Healthcare / Medical DevicesNZSE
$0.02
-0.00 (-10.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-2.2M · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-222.5%
↓Gross Margin
30.1%
↓Debt/Equity
0.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.7%
FCF CAGR
—
FCF margin
-133.7%
FCF / Net income
1.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.7M · net income $-2.2M · FCF $-2.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.7M | $1.7M | $2.1M | $1.7M | $1.7M |
| Net Income | $-2.2M | $-2.2M | $-2.1M | $-2.4M | $-7.9M |
| EBITDA | $-2.2M | $-2.2M | $-2.5M | $-2.9M | $-8.3M |
| EPS | -0.00 | -0.00 | -0.00 | -0.01 | -0.02 |
| Gross Margin | 30.1% | 30.1% | 31.8% | 27.7% | 31.1% |
| Operating Margin | -153.0% | -153.0% | -120.9% | -176.9% | -528.3% |
| Net Margin | -131.0% | -131.0% | -97.3% | -144.5% | -470.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.31 | 0.31 | — | — | — |
| Current Ratio | 3.29 | 3.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.3M | $-2.3M | $-2.0M | $-2.2M | $-2.5M |
| Returns | |||||
| ROE | -222.5% | -222.5% | -63.4% | -94.5% | -232.5% |
| Valuation | |||||
| P/B | 9.87 | 9.87 | 2.74 | 4.10 | 8.53 |
| Growth & Yield | |||||
| Revenue Growth | -18.8% | -18.8% | 26.8% | -0.9% | — |
| EPS Growth | 16.3% | 16.3% | 24.0% | 69.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.00
Residual
-40.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.